Skip to main content
Clinical Trials/NCT03355651
NCT03355651
Completed
Not Applicable

Prospective Study for Assess Efficacy and Tolerability of an Oral Supplement Based on Collagen, HC-15 and Plasmatic Proteins, in the Recovery of ACL After Surgery: a Multicenter, Randomized, Controlled Trial

OPKO Health, Inc.0 sites80 target enrollmentMarch 9, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ACL Reconstruction
Sponsor
OPKO Health, Inc.
Enrollment
80
Primary Endpoint
Pain improvement
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This was a prospective, multicenter, randomized, open-label, phase IV trial to compare the efficacy of supplementation with plasma proteins, hydrolyzed collagen (CH), a complex of HA-CS (HC-15), and vitamin C combined with a standard rehabilitation protocol versus the standard rehabilitation protocol only after arthroscopically-assisted functional ACL reconstruction with hamstrings.

Registry
clinicaltrials.gov
Start Date
March 9, 2015
End Date
March 3, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects aged between 18 and 55 years with partial or complete anterior cruciate ligament (ACL) rupture, diagnosed clinically and by Magnetic Resonance Imaging (MRI), requiring reconstructive surgery.
  • Patients with symptoms of acute or subacute ACL rupture (such as inflammation of the knee and pain with leg movement) or chronic ACL tear, including instability of the knee.
  • Patients with ACL ruptures without osteochondral lesions requiring additional surgery.
  • Patients with a medical history of therapeutic benefit using analgesic agents.

Exclusion Criteria

  • Patients with concomitant osteochondral pathology.
  • Patients treated with intra-articular injections of corticosteroids and/or platelet-rich plasma, or with oral glucosamine, CS, HA or CH in the two months prior to surgery.
  • Patients with systemic diseases, those treated with antibiotics or other drugs that might alter the healing process, and those who had undergone arthroscopic lavage in the 90 days prior to surgery.

Outcomes

Primary Outcomes

Pain improvement

Time Frame: 90 days

Assessed using a 100-mm Visual Analog Scale (VAS)

Secondary Outcomes

  • Number of rehabilitation sessions required(90 days)
  • Maduration of the graft(Day 0, day 90)
  • Knee function(90 days)
  • Analgesic consumption(90 days)

Similar Trials